Taro Yamashita

Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial

Masahisa Katsuno, Haruhiko Banno, Keisuke Suzuki et al. · The Lancet Neurology · 2010 · 187 citations

Jasmitt Study, Clinical Injury, Neurological Disorder +10

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 154 citations · Full text

Alzheimer's Disease, Open-label Extension Study, Medicine +5

Oxidative Stress Is Found in Amyloid Deposits in Systemic Amyloidosis

Yukio Ando, Nils Nyhlin, Ole B. Suhr et al. · Biochemical and Biophysical Research Communications · 1997 · 132 citations

Amyloid Deposits, Alzheimer's Disease, Biochemistry +6

Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His

Gregg Blevins, Robert Macaulay, Sheri Harder et al. · Neurology · 2003 · 76 citations

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Laura Obici, John L. Berk, Alejandra González‐Duarte et al. · Amyloid · 2020 · 71 citations · Full text